| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/11/2001 | WO2000062802A3 Vaccine comprising rsv antigen and cpg oligonucleotide |
| 01/11/2001 | WO2000062801A3 Combination vaccine against streptococcus pneumoniae and respiratory syncytial virus (rsv) |
| 01/11/2001 | WO2000062800A3 Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
| 01/11/2001 | WO2000062657A3 Improvement of t cell mediated immunity |
| 01/11/2001 | WO2000061747A3 Clasp-2 transmembrane proteins |
| 01/11/2001 | WO2000061543A3 Esters of l-carnitine or alkanoyl l-carnitines |
| 01/11/2001 | WO2000059515A3 Immunomodulating polymers |
| 01/11/2001 | WO2000054803A3 Immunostimulatory nucleic acids and antigens |
| 01/11/2001 | WO2000053748A3 Casb618 polynucleotides and polypeptides and their use |
| 01/11/2001 | WO2000053216A3 Use of casb616 polypeptides and polynucleotides for cancer treatment |
| 01/11/2001 | WO2000053215A3 Deglycosylated ricin toxin a-chain vaccine |
| 01/11/2001 | WO2000051635A3 Emulsan and emulsan analogs immunization formulations and use |
| 01/11/2001 | WO2000050075A3 Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs |
| 01/11/2001 | WO2000046251A3 Human polyclonal antibodies from transgenic nonhuman animals |
| 01/11/2001 | WO2000032226B1 Xenograft animal model for the induction of papillomas, the production of papillomavirus and the propagation thereof |
| 01/11/2001 | WO2000029561A8 Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope |
| 01/11/2001 | WO1995016779A9 Herpes-symplex-virus type 2 icp4 protein and its use in a vaccine composition |
| 01/11/2001 | DE19931883A1 DNA kodierend für Beta-Tubulin und deren Verwendung DNA coding for beta-tubulin, and the use thereof |
| 01/11/2001 | DE19930177A1 Intermolekular assoziierende Verbindungen und diese umfassende Aggregate Inter-molecular compounds and associating this comprehensive aggregates |
| 01/11/2001 | DE19929887A1 cDNA-Sequenzen von zwei Interakoren FANCIP2 und FANCIP3 des Fanconi-Anämie-Proteins der Komplementationsgruppe A cDNA sequences of two Interakoren FANCIP2 and FANCIP3 of the Fanconi anemia complementation group A-protein of the |
| 01/11/2001 | CA2380875A1 Cell death related drug targets in yeast and fungi |
| 01/11/2001 | CA2378539A1 Adenovirus carrying gag gene hiv vaccine |
| 01/11/2001 | CA2377731A1 Fusion peptides comprising a peptide ligand domain and a multimerization domain |
| 01/11/2001 | CA2377381A1 Neovascular-targeted immunoconjugates |
| 01/11/2001 | CA2373885A1 Therapeutic agent for diseases caused by pth or pthrp |
| 01/11/2001 | CA2373884A1 Method for enhancing an immune response |
| 01/11/2001 | CA2372935A1 Novel antifungal agents and fungicides, method for the production thereof and their use |
| 01/10/2001 | EP1067141A1 A male-specific protein homologue involved in histocompatibility |
| 01/10/2001 | EP1066396A1 Nucleic acid transfer vectors, compositions containing same and uses |
| 01/10/2001 | EP1066391A2 Antigen preparation and use |
| 01/10/2001 | EP1066383A1 Porcine reproductive and respiratory syndrome oral vaccine production in plants |
| 01/10/2001 | EP1066376A1 Bacteria attenuated by a non-reverting mutation in each of the aroc, ompf and ompc genes, useful as vaccines |
| 01/10/2001 | EP1066375A2 $i(LACTOBACILLI) HARBORING AGGREGATION AND MUCIN BINDING GENES AS VACCINE DELIVERY VEHICLES |
| 01/10/2001 | EP1066370A1 Stimulated monocyte derived cells, their preparation and uses |
| 01/10/2001 | EP1066321A2 Formulation having a papilloma virus-specific protein, and the production and use thereof |
| 01/10/2001 | EP1066319A1 Production methods and uses of a retrovirus |
| 01/10/2001 | EP1066310A1 Neokine protein and nucleic acid molecules and uses therefor |
| 01/10/2001 | EP1066058A1 Methods and means for the treatment of immune related diseases |
| 01/10/2001 | EP1066055A1 Adjuvant-containing vaccines |
| 01/10/2001 | EP1066054A2 Use of active p40 conjugates for nasal delivery |
| 01/10/2001 | EP1066053A1 Hib/dtpa vaccine composition and methods of preparation |
| 01/10/2001 | EP1066052A2 Mesenchymal stem cells for prevention and treatment of immune responses in transplantation |
| 01/10/2001 | EP1066051A1 Sciellin and uses thereof |
| 01/10/2001 | EP1066043A2 Materials and methods relating to the treatment of conditions involving mast cells, basophils and eosinophils |
| 01/10/2001 | EP1066028A2 Methods and devices for modulating the immune response |
| 01/10/2001 | CN1279718A Fusion proteins comprising HIV-1 Tat and/or Nef proteins |
| 01/10/2001 | CN1279713A Cellular immunogenicity potentiating composition containing alpha-glycosylceramide |
| 01/10/2001 | CN1279692A Anti-idiotype monoclonal antibodise, their use in active immunotherapy of malignant tumors and compositions containing them |
| 01/10/2001 | CN1279691A Antibodise against phosphorylated VASP (vasodilator-stimulated phosphoprotein), hybridoma cells for their preparation, and their use |
| 01/10/2001 | CN1279690A Soluble single-chain T-cell receptor proteins |
| 01/10/2001 | CN1279689A Vitamin D receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof |
| 01/10/2001 | CN1279688A Viral clearance process |
| 01/10/2001 | CN1279616A Synergistic composition and methods for treating neoplanstic or cancerous growths and for restoring or boosting hematopoiesis |
| 01/10/2001 | CN1279290A Human signal recognition particle receptor beta and its coding sequence, preparing process and application |
| 01/10/2001 | CN1279289A Human P47 protein and its coding sequence |
| 01/10/2001 | CN1060392C Medicine for curing recurrent stomatocace and Behcet's syndrome |
| 01/09/2001 | US6172213 Anti-IgE antibodies and method of improving polypeptides |
| 01/09/2001 | US6172201 Cellular receptor for HIV-1 Vpr essential for G2/M phase |
| 01/09/2001 | US6172194 ARF-p19, a novel regulator of the mammalian cell cycle |
| 01/09/2001 | US6172193 Escape mutant of the surface antigen of hepatitis B virus |
| 01/09/2001 | US6172192 Polypeptide or peptide associated microorganism infection; for diagnosis and prevention protozoan infection of mammals |
| 01/09/2001 | US6172189 Polypeptide for the detection of antibodies associated with preferential viral diseases and infection |
| 01/09/2001 | US6172186 Pseudorabies virus protein |
| 01/09/2001 | US6172107 Mycophenolate salt disintegrates selectively in intestines |
| 01/09/2001 | US6172047 Therapy for nervous system tumors |
| 01/09/2001 | US6171854 Yellow fever infectious cDNA and plasmids |
| 01/09/2001 | US6171840 LacC from streptococcus pneumoniae |
| 01/09/2001 | US6171838 ratB |
| 01/09/2001 | US6171835 ribH |
| 01/09/2001 | US6171830 Efficient purification of mycolic acids, salts or derivatives by dissolving mixture in bi-phasic solvent, subjecting to countercurrent distribution separation with sufficient cycles, then recovering |
| 01/09/2001 | US6171820 Saturation mutagenesis in directed evolution |
| 01/09/2001 | US6171806 Isolated peptide defined by SEQ ID NO: 17 and uses thereof |
| 01/09/2001 | US6171803 Drug screening for allergy treatments by engineering expression of alpha, beta, and gamma subunits of receptor in host cell, incubating with candidate inhibitor, and analyzing for cell expression or cell activation |
| 01/09/2001 | US6171799 Immunoassay detection of a v beta 5.3 t cell by contacting tissue sample with a monoclonal antibody which reacts to variable region of beta chain of the receptor; diagnosis and treatment of rheumatoid arthritis |
| 01/09/2001 | US6171783 Detecting parainfluenza virus-3 and respiratory syncytial virus infection by using fusion protein of antigenic proteins from both viruses |
| 01/09/2001 | US6171782 Antibody compositions to HCV and uses thereof |
| 01/09/2001 | US6171598 GTP cyclohydrolase II (RIBA) |
| 01/09/2001 | US6171597 Adeno-associated virus vector for boosting immunogenicity of freshly isolated tumor cells |
| 01/09/2001 | US6171596 Immunostimulants; genetic engineering |
| 01/09/2001 | US6171591 Recombinant nodavirus compositions and methods |
| 01/09/2001 | US6171590 Treatment and prevention of inflammatory responses. |
| 01/09/2001 | US6171589 Are useful in protecting individuals against infections by species of the genus mycoplama. |
| 01/09/2001 | US6171588 Anti-αvβ3 integrin antibody antagonists |
| 01/09/2001 | US6171586 Antibody formulation |
| 01/04/2001 | WO2001000877A2 Method of isolation of regulated virulence determinants from bacterial pathogens |
| 01/04/2001 | WO2001000874A2 Cancer associated antigens and uses therefor |
| 01/04/2001 | WO2001000864A2 Nucleic acid binding of multi-zinc finger transcription factors |
| 01/04/2001 | WO2001000857A1 Delivery system |
| 01/04/2001 | WO2001000839A1 Tetanus toxin polypeptides |
| 01/04/2001 | WO2001000837A1 Basb111 polypeptide and polynucleotide from moraxella catharrhalis |
| 01/04/2001 | WO2001000836A1 Novel compounds |
| 01/04/2001 | WO2001000835A1 Moraxella catarrhalis polypeptides |
| 01/04/2001 | WO2001000829A2 Human endogenous retrovirus in breast cancer |
| 01/04/2001 | WO2001000828A2 Compositions and methods for the therapy and diagnosis of lung cancer |
| 01/04/2001 | WO2001000822A2 Cdna sequences of two interacting fancip2 and fancip3 of the fanconi anemia complementation group a protein |
| 01/04/2001 | WO2001000796A2 Glycosyltransferases of helicobacter pylori |
| 01/04/2001 | WO2001000790A1 Production of the lipidated form of the peptidoglycan-associated lipoproteins of gram-negative bacteria |
| 01/04/2001 | WO2001000784A2 Compound derived from an offset orf of the ice gene |
| 01/04/2001 | WO2001000665A2 Inhibitors of memapsin 2 and use thereof |
| 01/04/2001 | WO2001000664A2 Secreted alpha-helical protein-36 |